Every one of those 1 sits in a single category, markets. Avidity Biosciences, Inc. is most often covered alongside Atrium Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Avidity Biosciences, Inc.
Every one of those 1 sits in a single category, markets. Avidity Biosciences, Inc. is most often covered alongside Atrium Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6 for that window. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. We currently track 1 Finance story that mention Avidity Biosciences, Inc., all published on March 3, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Avidity Biosciences, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
Avidity Biosciences, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.